|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 158.35 EUR | -1.65% |
|
-1.41% | +35.80% |
| 04/08 | Marengo Therapeutics, Inc. and Ipsen S.A. Nominate First Drug Candidate Under Strategic Tristar Collaboration | CI |
| 03/08 | Jefferies Downgrades Ipsen to Underperform, Boosts PT | MT |
| Market Cap | 1.3TCr 1.5TCr 1.21TCr 1.11TCr 2.09TCr 1,43000Cr 2.12TCr 14TCr 5.58TCr 72TCr 5.63TCr 5.51TCr 2,38200Cr | P/E 2026 * |
13.4x | P/E 2027 * | 14.2x |
|---|---|---|---|---|---|
| Enterprise Value | 1.17TCr 1.36TCr 1.1TCr 1TCr 1.89TCr 1,29400Cr 1.92TCr 13TCr 5.05TCr 65TCr 5.09TCr 4.98TCr 2,15600Cr | EV / Sales 2026 * |
2.58x | EV / Sales 2027 * | 2.35x |
| Free-Float |
40.65% | Yield 2026 * |
0.95% | Yield 2027 * | 0.95% |
Last Transcript: Ipsen
| 1 day | -1.65% | ||
| 1 week | -1.41% | ||
| Current month | -6.17% | ||
| 1 month | -3.93% | ||
| 3 months | -3.53% | ||
| 6 months | +17.58% | ||
| Current year | +35.80% |
| 1 week | 153.8 |  | 161.2 |
| 1 month | 153.8 | | 171.8 |
| Current year | 116.5 | | 172.7 |
| 1 year | 105.9 | | 172.7 |
| 3 years | 90.2 | | 172.7 |
| 5 years | 77.76 | | 172.7 |
| 10 years | 36.84 | | 172.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Loew
CEO | Chief Executive Officer | 59 | 01/07/2020 |
| Chief Executive Officer | 57 | 01/01/2020 | |
Pierrick Lefranc
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Antoine Flochel
BRD | Director/Board Member | 61 | 30/08/2005 |
| Chairman | 68 | 22/11/2010 | |
Carol Xueref
BRD | Director/Board Member | 69 | 01/06/2012 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.65% | -1.41% | - | - | 1.53TCr | |
| +3.65% | +8.11% | +90.85% | +132.54% | 1,05700Cr | |
| +0.23% | +2.04% | +49.36% | +50.79% | 62TCr | |
| +0.01% | -0.31% | +23.01% | +61.35% | 43TCr | |
| +1.58% | +4.80% | +51.48% | +39.79% | 36TCr | |
| +0.65% | +1.85% | +32.06% | +39.99% | 30TCr | |
| +0.79% | +4.26% | +8.64% | +7.42% | 25TCr | |
| +0.87% | +8.73% | +44.49% | +57.19% | 22TCr | |
| +0.34% | +1.27% | -5.10% | -50.94% | 21TCr | |
| -0.18% | +1.55% | +10.55% | +66.48% | 17TCr | |
| Average | +0.49% | +0.94% | +33.93% | +44.96% | 40.23TCr | |
| Weighted average by Cap. | +1.03% | +1.33% | +49.10% | +66.20% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 455.31Cr 525.94Cr 425.58Cr 388.95Cr 732.96Cr 50TCr 744.42Cr 4.99TCr 1.96TCr 25TCr 1.97TCr 1.93TCr 84TCr | 457.09Cr 528Cr 427.24Cr 390.47Cr 735.82Cr 50TCr 747.32Cr 5.01TCr 1.97TCr 25TCr 1.98TCr 1.94TCr 84TCr |
| Net income | 100.15Cr 115.69Cr 94Cr 86Cr 161.23Cr 11TCr 163.75Cr 1.1TCr 430.75Cr 5.52TCr 434.41Cr 424.93Cr 18TCr | 96Cr 110.93Cr 90Cr 82Cr 154.6Cr 11TCr 157.01Cr 1.05TCr 413.04Cr 5.29TCr 416.54Cr 407.46Cr 18TCr |
| Net Debt | -123.25Cr -142.37Cr -115.2Cr -105.29Cr -198.41Cr -14TCr -201.52Cr -1.35TCr -530.1Cr -6.79TCr -534.6Cr -522.94Cr -23TCr | -224.1Cr -258.86Cr -209.46Cr -191.44Cr -360.75Cr -25TCr -366.39Cr -2.46TCr -963.82Cr -12TCr -972Cr -950.8Cr -41TCr |
| Date | Price | Change |
|---|---|---|
| 10/26/10 | €161.20 | +0.12% |
| 07/26/07 | €161.00 | +1.32% |
| 06/26/06 | €158.90 | +1.15% |
| 05/26/05 | €157.10 | +0.32% |
| 04/26/04 | €156.60 | -4.22% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- IPN Stock
- I7G Stock
Select your edition
All financial news and data tailored to specific country editions
